Predict pre-eclampsia earlier through improved biomarkers.
Our PlGF (Placental Growth Factor) assay was the first developed commercially for first trimester screening. Used in combination with biophysical markers and established risk factors, it is particularly effective for detecting preterm pre-eclampsia before 13 weeks gestation.
As additional safeguards for patients at later stages of pregnancy, the PlGF assay can also be used as part of the same combination of markers in the second and third trimesters.
PerkinElmer biochemistry assays and measuring instruments are complemented by essential items such as native controls to ensure the integrity of results. We also supply dedicated pre-eclampsia screening software for critical first trimester risk calculations. Together, these products constitute a complete, practical solution for pre-eclampsia prediction.
PerkinElmer aneuploidy and pre-eclampsia screening products are not available in the USA. Products may not be available in all countries. For information on availability, please contact your local representative.
AutoDELFIA® immunoassay system for prenatal screening is supported by the widest available range of prenatal analytes available on any platform. Reliable and easy to use AutoDELFIA instrument offers high quality results both for aneuploidy and pre-eclampsia risk assessment during pregnancy.
The VICTOR2™ D fluorometer is designed for all PerkinElmer diagnostic and screening assays based on either time-resolved fluorescence or prompt fluorescence. VICTOR2 D includes MultiCalc software for assay evaluation and quality control.
The DELFIA®/AutoDELFIA® PlGF kit quickly and accurately detects levels of Placental Growth Factor (PlGF) in maternal serum. The kit may be used with either the AutoDELFIA automated immunoassay system or the manual DELFIA system.